Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that RASUVO (methotrexate) solu...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Federal Register
- Region
- USA
- Scope
- Regulatory
- Published
- July 22, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
The Food and Drug Administration (FDA, Agency, or we) has determined that RASUVO (methotrexate) solu...
Source route
Continue on federalregister.gov
Leave the platform to read the original full article on the publisher site.
Source: Federal Register
Scope: Regulatory
Related coverage
More related coverage
Annual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2025 to 2026
Trends in MRSA, MSSA, E. coli, Klebsiella spp. and P. aeruginosa bacteraemia and C. difficile infect...
Submission for Office of Management and Budget Review; Generic for Administration for Children and Families Program Monitoring Activities
The Administration for Children and Families (ACF) intends to request from the Office of Management...
Center for Scientific Review; Notice of Closed Meetings
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Notifications Submission
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has b...